gastric juice protein is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
On 20 September 2023, Florida outlawed tianeptine, classifying it as a schedule I substance by an administrative edict issued by the Florida Attorney General. In July 2026, the United States Drug Enforcement Administration (DEA) announced its intention to make tianeptine a Schedule I controlled substance.
Xi said "China keeps its door wide open, welcomes American companies wanting to invest and do business there" and hoped that "Chinese companies are treated fairly here in the US". Xi said "Both China and the United States are leading nations in artificial intelligence. We have both the capability and responsibility to develop and manage AI for good, and ensure that the development of AI is always under human control and serves the well-being of the people". He called for cooperation on trade. He said "We do not need to avoid mentioning competition, but our competition should be a healthy one and should be kept within bounds" and that "It should be a race of catching up with one another, not a wrestle in which one either wins or loses. China and the United States must hold the line of no conflict and no confrontation between us". Xi said the militaries "should maintain regular dialog and improve mechanisms for crisis communication and prevention. The 'Thucydides trap' can be overcome". Xi said Chinese and US soldiers have fought "shoulder to shoulder against fascist aggression" and that "Chinese people have never forgotten that part of history, nor have the American people". He announced an invitation for 100,000 young Americans to study in exchange programmes in China over the next five years. He also announced two pandas, Ping Ping and Fu Shuang, would be sent to Zoo Atlanta.
Hydrogen peroxide is most commonly available as a solution in water. For consumers, it is usually available from pharmacies at 3 and 6 wt% concentrations. The concentrations are sometimes described in terms of the volume of oxygen gas generated; one milliliter of a 20-volume solution generates twenty milliliters of oxygen gas when completely decomposed. For laboratory use, 30 wt% solutions are most common. Commercial grades from 70% to 98% are also available, but due to the potential of solutions of more than 68% hydrogen peroxide to be converted entirely to steam and oxygen (with the temperature of the steam increasing as the concentration increases above 68%) these grades are potentially far more hazardous and require special care in dedicated storage areas. Buyers must typically allow inspection by commercial manufacturers.
A 2003 technical report by the World Health Organization provided evidence that high intake of sugary drinks (including fruit juice) increases the risk of obesity by adding to overall energy intake. By itself, sugar is not a factor causing obesity and metabolic syndrome, but rather its excessive consumption adds to caloric burden, which meta-analyses showed could increase the risk of developing type 2 diabetes and metabolic syndrome in adults and children.
Sources: en.wikipedia.org
Murphree developing centrifuges, and Arthur Compton responsible for theoretical studies and design. On 23 April 1942, Met Lab scientists discussed seven possible ways to extract plutonium from irradiated uranium, and decided to pursue investigation of all seven. On 17 June, the first batch of uranium nitrate hexahydrate (UNH) was undergoing neutron bombardment in the Washington University in St. Louis cyclotron. On 27 July, the irradiated UNH was ready for Glenn T. Seaborg's team. On 20 August, using ultramicrochemistry techniques, they successfully extracted plutonium. In May 1942, Gertrude Scharff Goldhaber at Brookhaven National Laboratory reports for the first the emission of multiple neutrons during spontaneous fission of uranium. Her research was kept a secret. In April 1939, creating a chain reaction in natural uranium became the goal of Fermi and Szilard, as opposed to isotope separation. Their first efforts involved five hundred pounds of uranium oxide from the Eldorado Radium Corporation. Packed into fifty-two cans two inches in diameter and two feet long in a tank of manganese solution, they were able to confirm more neutrons were emitted than absorbed. However, the hydrogen within the water absorbed the slow neutrons necessary for fission. Carbon in the form of graphite, was then considered, because of its smaller capture cross section. In April 1940, Fermi was able to confirm carbon's potential for a slow-neutron chain reaction, after receiving National Carbon Company's graphite bricks at their Pupin Laboratories.
With insect stings, a large local reaction may occur as an area of skin redness greater than 10 cm in size that can last one to two days. This reaction may also occur after immunotherapy. The skin forms an effective barrier to the entry of most allergens, but this barrier cannot withstand everything. For example, an insect sting can breach the barrier and inject allergen into the affected spot. When an allergen enters the epidermis or dermis, it triggers a localized allergic reaction which activates the mast cells in the skin resulting in an immediate increase in permeability of blood vessels, leading to fluid leakage and swelling in the affected area. Mast-cell activation also stimulates a skin lesion called the wheal-and-flare reaction. Then the release of chemicals from local nerve endings by a nerve axon reflex causes the widening of surrounding cutaneous blood vessels, which causes redness of the surrounding skin. As part of the allergic response, the body has developed a secondary response that, in some individuals, causes a more widespread and sustained skin swelling. This usually occurs about 8 hours after the allergen originally comes in contact with the skin. When an allergen is ingested, a dispersed form of wheal-and-flare reaction, known as urticaria or hives, will appear when the allergen enters the bloodstream and eventually reaches the skin. This same skin reactivity allows allergists to test for existing allergies by injecting a small amount of an allergen into the skin, which causes a reaction at the injection site.
This nuclide was long thought to be stable, but in 2003 it was found to be unstable, with a very long half-life of 20.1 billion billion years; it is the last step in the chain before stable thallium-205. Because this bottleneck is so long-lived, very small quantities of the final decay product have been produced, and for most practical purposes bismuth-209 is the final decay product. In the past, during the first few million years of the history of the Solar System, there were more unstable high-mass nuclides in existence, and the four chains were longer, as they included nuclides that have since decayed away. Notably, 244Pu, 237Np, and 247Cm have half-lives over a million years and would have then been bottlenecks higher in the 4n, 4n+1, and 4n+3 chains respectively - 244Pu and 247Cm have been identified as having been present. (There is no nuclide with a half-life over a million years above 238U in the 4n+2 chain.) Today some of these formerly extinct isotopes are again in existence as they have been manufactured. Thus they again take their places in the chain: plutonium-239, used in nuclear weapons, is the major example, decaying to uranium-235 via alpha emission with a half-life 24,500 years. There has also been large-scale production of neptunium-237, resurrecting the extinct fourth chain. The tables below hence start the four decay chains at isotopes of californium with mass numbers from 249 to 252.
Sources: en.wikipedia.org
== Occurrence == Pyrite is the most common of sulfide minerals and is widespread in igneous, metamorphic, and sedimentary rocks. It is a common accessory mineral in igneous rocks, where it also occasionally occurs as larger masses arising from an immiscible sulfide phase in the original magma. It is found in metamorphic rocks as a product of contact metamorphism. It also forms as a high-temperature hydrothermal mineral, though it occasionally forms at lower temperatures. Pyrite occurs both as a primary mineral, present in the original sediments, and as a secondary mineral, deposited during diagenesis. Pyrite and marcasite commonly occur as replacement pseudomorphs after fossils in black shale and other sedimentary rocks formed under reducing environmental conditions. Pyrite is common as an accessory mineral in shale, where it is formed by precipitation from anoxic seawater, and coal beds often contain significant pyrite. Notable deposits are found as lenticular masses in Virginia, U.S., and in smaller quantities in many other locations. Large deposits are mined at Rio Tinto in Spain and elsewhere in the Iberian Peninsula.
Pre-tRNAs undergo extensive modifications inside the nucleus. Some pre-tRNAs contain introns that are spliced, or cut, to form the functional tRNA molecule; in bacteria these self-splice, whereas in eukaryotes and archaea they are removed by tRNA-splicing endonucleases. Eukaryotic pre-tRNA contains bulge-helix-bulge (BHB) structure motif that is important for recognition and precise splicing of tRNA intron by endonucleases. This motif position and structure are evolutionarily conserved. However, some organisms, such as unicellular algae have a non-canonical position of BHB-motif as well as 5′- and 3′-ends of the spliced intron sequence. The 5′ sequence is removed by RNase P, whereas the 3′ end is removed by the tRNase Z enzyme. A notable exception is in the archaeon Nanoarchaeum equitans, which does not possess an RNase P enzyme and has a promoter placed such that transcription starts at the 5′ end of the mature tRNA. The non-templated 3′ CCA tail is added by a nucleotidyl transferase. Before tRNAs are exported into the cytoplasm by Los1/Xpo-t, tRNAs are aminoacylated. The order of the processing events is not conserved. For example, in yeast, the splicing is not carried out in the nucleus but at the cytoplasmic side of mitochondrial membranes.
The oral sugar test also requires giving the horse only a single flake of hay at 10pm the night before the test. The following morning, karo corn syrup is given orally, and glucose and insulin levels are measured at 60 and 90 minutes after administration. Normal or excessively high insulin levels are diagnostic. However, equivocal test results require retesting at a later date, or performing a different test. A similar test is available outside the US, in areas where corn-syrup products are less readily available, where horses are given a morning meal of chaff with dextrose powder, and blood insulin levels are measured 2 hours later. Dynamic testing for insulin has higher sensitivity test than fasting insulin concentration, because insulin resistance may only become evident when challenged by hyperglycemia. There are various tests available for measuring changes in insulin concentration. They usually require a similar fasting protocol as the fasting insulin test.
== Function == CENPA is a protein which epigenetically defines the position of the centromere on each chromosome, determining the position of kinetochore assembly and the final site of sister chromatid cohesion during mitosis. This proteins is frequently accompanied by "centrochromatin"-associated changes to canonical histones and is constitutively present in centromeres. The CENPA protein is a histone H3 variant which replaces one or both canonical H3 histones in a subset of nucleosomes within centromeric chromatin. CENPA has the greatest sequence divergence of the histone H3 variants, with just 48% similarity to canonical histone H3, and has a highly diverged N-terminal tail that lacks many well characterised histone modification sites including H3K4, H3K9 and H3K27. Unusually for a histone, CENPA nucleosomes are not loaded together with DNA replication and are loaded at different cell cycle stages in different organisms: G1 phase in human, M phase in drosophila, G2 in S. pombe. To orchestrate this specialised loading there are CENPA-specific histone chaperones: HJURP in human, CAL1 in drosophila, nefr-1 in C. elegans and Scm3 in S. pombe. In most eukaryotes CENPA is loaded into large domains of highly repetitive satellite DNA. The position of CENPA within satellite DNA are heritable at the protein level through a purely epigenetic mechanism. This means that the position of CENPA protein binding to the genome is copied upon cell division to the two daughter cells independent of the underlying DNA sequence.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.